15:18 , Sep 14, 2018 |  BC Week In Review  |  Company News

GNS, Amgen to use AI to explore patient response to mCRC drug Vectibix

GNS Healthcare Inc. (Cambridge, Mass), Amgen Inc. (NASDAQ:AMGN) and the Alliance for Clinical Trials in Oncology (Boston, Mass.) partnered to use artificial intelligence to identify factors that drive and predict patient responses to Amgen’s metastatic...
14:59 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

Exelixis, Ipsen report additional Phase II data for cabozantinib in untreated RCC

In September, Exelixis Inc. (NASDAQ:EXEL) and partner Ipsen Group (Euronext:IPN; Pink:IPSEY) reported additional data from the open-label Phase II CABOSUN trial in 157 patients with previously untreated advanced renal cell carcinoma (RCC) showing that first-line...
07:00 , Sep 5, 2016 |  BioCentury  |  Strategy

Back to School: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Cabometyx cabozantinib: Phase II data

Top-line data from the open-label Phase II CABOSUN trial in 157 patients with previously untreated advanced RCC showed that first-line treatment with once-daily 60 mg oral Cabometyx met the primary endpoint of improving PFS vs....
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

Midostaurin: Phase III data

Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland   Product: Midostaurin ( PKC412 , CGP 41251 )   Business: Cancer   Molecular target: FMS-like tyrosine kinase 3 (FLT3) (CD135) ; Stem cell factor (SCF) receptor tyrosine kinase...
02:17 , May 12, 2015 |  BC Extra  |  Company News

Project Data Sphere tops first-year target

Data-sharing consortium Project Data Sphere LLC said on Monday that it accrued comparator-arm clinical trial data from 26,000 patient lives, which surpassed the first-year target of 25,000 lives the not-for-profit set when the CEO Roundtable...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

Tarceva erlotinib: Phase III started

The National Clinical Trials Network (NCTN) launched the ALCHEMIST protocol to identify early stage NSCLC patients with tumors that harbor genetic mutations to understand how early intervention can improve survival outcomes for patients who have...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

Xalkori crizotinib: Phase III started

The National Clinical Trials Network (NCTN) launched the ALCHEMIST protocol to identify early stage NSCLC patients with tumors that harbor genetic mutations to understand how early intervention can improve survival outcomes for patients who have...
00:30 , Aug 19, 2014 |  BC Extra  |  Clinical News

NCI launches second precision medicine master protocol

The National Clinical Trials Network (NCTN) launched the ALCHEMIST protocol to identify early stage non-small cell lung cancer (NSCLC) patients with tumors that harbor genetic mutations to understand how early intervention can improve survival outcomes...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Clinical News

Prophage vitespen: Updated Phase II data

Updated data from a single-arm, U.S. Phase II trial in 46 patients with newly diagnosed GMB showed that intradermal Prophage G-100 plus standard of care (SOC) radiation and temozolomide led to a median PFS of...